In a research note ahead of a meeting of the American Association for the Study of Liver Diseases, or AASLD, Piper Sandler analyst Yasmeen Rahimi called Madrigal Pharmaceuticals’ (MDGL) interim analysis from the MAESTRO-NAFLD trial on Friday “one of the most highly anticipated data readouts” in the nonalcoholic steatohepatitis, or NASH, landscape. The analyst added… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3195613/-Before-the-Move-Watch-Madrigal-Pharmaceuticals-ahead-of-AASLD-meeting)
previous post